Navigation Links
BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Date:9/19/2007

BIRMINGHAM, Ala., Sept. 19 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary findings from a Phase II study with intramuscular (i.m.) injection of peramivir, the Company's product candidate for the treatment of seasonal and life-threatening influenza.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO )

The study was a randomized, double-blind, placebo-controlled clinical trial designed to test whether peramivir, when administered acutely in high doses intramuscularly, could reduce the duration of symptoms during seasonal influenza. 344 patients who had a positive rapid antigen test indicating acute influenza illness were randomized to receive intramuscular injections of either placebo or one of two dose levels of peramivir (150mg and 300mg) as a single dose administered within 48 hours of symptom onset. The primary endpoint of the study was the time to alleviation of symptoms in the patients with confirmed influenza infection (n=313).

While the results indicate that in the evaluable population of 313 subjects, a single dose of peramivir demonstrated a treatment improvement over placebo, the improvement was not statistically significant. With regard to the primary endpoint of median time to alleviation of symptoms, the improvement over placebo was 22.9 hours with the 150mg dose (p=0.284) and 21.1 hours with the 300mg dose (p=0.152). Based on a preliminary review, the Company believes that due to the introduction of a shorter injection needle in the Phase II trial compared to the Phase I trial, only one-third of subjects received an adequate intramuscula
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... June 30, 2015. Biorem,s complete second quarter financial statements and MD&A ... HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six -months endedJune ... 2015 , 2014 Revenue , 4,709 ... Gross profit , 1,656 , 56 , ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... CONCORD, Calif., May 4 Pulse Systems announced today ... credit facility through the Structured Finance Group at Fifth ... $7.0 million term loan and a $1.5 million revolving ... credit arrangement of this scope in today,s challenging banking ...
... May 4 Arno Therapeutics, Inc. (OTC Bulletin Board: ... today announced that it has voluntarily filed a Form ... order to deregister its common stock under the Securities ... effective immediately, Arno,s obligation to file periodic and other ...
... SALT LAKE CITY, May 4 Amedica Corporation, ... ceramic technologies, announced today that it has received ... of their spinal intervertebral spacers using novel CSC ... using Amedica,s novel silicon nitride ceramic, offers a ...
Cached Biology Technology:Pulse Systems Announces New $8.5 Million Credit Facility 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3Amedica Receives CE Mark for Valeo(TM) Ceramic Spinal Implant System Incorporating CSC Technology 2
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... Singapore,s leading science and technology university has formed ... of Scientific Research (Centre National de la Recherche ... in France, and Thales the French electronics giant ... defence, security and transportation industries. The alliance ...
... and cures for life-threatening childhood illnesses in children,s DNA ... the decision as to who should have access to ... says a Tel Aviv University researcher in a recent ... by colleagues from The Netherlands and Canada. The recommendations, ...
... Expectant mothers who eat excessive quantities of liquorice during ... a study has shown. A study of eight ... liquorice when pregnant found they did not perform as ... were also more likely to have poor attention spans ...
Cached Biology News:New Singapore-France research alliance to develop state-of-the-art nanotechnologies 2New Singapore-France research alliance to develop state-of-the-art nanotechnologies 3Keeping DNA 'all in the family' 2Keeping DNA 'all in the family' 3Eating liquorice in pregnancy may affect a child's IQ and behavior 2
... 293 cells were cultured in Minimum Essential Medium ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... is an aqueous solution that contains a ... in a PBS buffer (phosphate buffered saline), ... contains a combination of 0.02% methylisothiazolone and ... Plus Stabilizer provides optimum performance for both ...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
Biology Products: